Mevalonate pathway blockage enhances the efficacy of mTOR inhibitors with the activation of retinoblastoma protein in renal cell carcinoma.
Hagiwara N, Watanabe M, Iizuka-Ohashi M, Yokota I, Toriyama S, Sukeno M, Tomosugi M, Sowa Y, Hongo F, Mikami K, Soh J, Fujito A, Miyashita H, Morioka Y, Miki T, Ukimura O, Sakai T.
Hagiwara N, et al. Among authors: morioka y.
Cancer Lett. 2018 Sep 1;431:182-189. doi: 10.1016/j.canlet.2018.05.025. Epub 2018 May 17.
Cancer Lett. 2018.
PMID: 29778569